🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — March 20, 2026

High-value federal contracts totaling $3.1B over the March 20, 2026 period underscore bullish momentum in border/prison construction ($1.6B, 52% of total) and IT/cyber services ($470M, 15%), with 9/12 signals bullish and significant options upside averaging 50% above obligations. Institutional investors should prioritize exposure to commercial construction (NAICS 236220) leaders like Spencer and Clark, alongside IT firms (NAICS 541512) such as GDIT and Cognosante, amid long-term performance periods to 2030. Neutral NASA R&D awards to nonprofits ($565M) offer stability but limited equity upside, while firm-fixed-price prevalence flags execution risks on 70% of contracts.

12 total filings
· daily

DOE Energy Grants — March 20, 2026

DOE/NNSA awarded a $110M firm fixed price contract (potential $357M with options) to BWXT ENRICHMENT OPERATIONS, LLC for domestic uranium enrichment engineering support, with $67M already outlayed providing immediate revenue visibility through 2030. This non-competitive award to a small business signals strong federal commitment to U.S. uranium capabilities amid nuclear energy priorities. Investors should monitor option exercises and follow-on tasks for multi-year upside in the nuclear supply chain.

1 total filings
· daily

General Federal Contracts — March 20, 2026

Federal contracts totaling $3.08B highlight bullish momentum in construction and IT sectors, led by a $1.15B DHS border barrier award to Spencer Construction and multi-hundred million prison/IT projects. Nine of 12 signals are bullish, with average option upside of ~50% across awards, signaling revenue visibility through 2026-2030. Neutral NASA R&D contracts to nonprofits provide stability but limited equity upside, while firm-fixed-price structures flag execution risks amid long tenors.

12 total filings
· daily

All NASA Contracts — March 20, 2026

NASA's three contracts totaling $565M underscore stable funding for space R&D infrastructure (JPL FFRDC) and talent development through 2027, with 83% ($472M) concentrated at Caltech and average 79% outlay ($446M spent). All neutral signals reflect predictable nonprofit cash flows amid full obligations exercised but limited direct equity plays. Investors gain visibility into NASA commitment but face budget-dependent tail risks on $119M remaining.

3 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 20, 2026

Across 46 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly interpreted to include adjacent defensive sectors like pharma and logistics), dominant themes include robust revenue growth in 6/12 companies reporting financials (avg +100% YoY, e.g., Belpointe PREP +244%, Yellowstone +52%, Cellectis +61.7%), offset by mixed profitability with 4/12 showing widening net losses (avg +60% YoY deterioration). SPAC and M&A activity peaks with Pelican-Greenland merger approval despite 63% redemptions, Constellation-Calpine completion, and pending KORE $9.25/share cash deal, signaling consolidation. Proxy statements (12/46) highlight 2025 successes like Eli Lilly's $65.2B revenue/40% TSR outperformance and Penske's $31.8B revenue/$182M buybacks, fostering bullish sentiment amid AGMs in Apr-May 2026. Risks emerge from Nasdaq bid price deficiencies (Faraday Future, TELA Bio), repeated insider debt extensions (Perfect Moment), and leadership churn (CleanCore CEO resignation). Capital allocation leans shareholder-friendly with dividends (Helios $0.12/share, Apr27 record) and buybacks, but high debt growth (Belpointe +47% YoY) flags leverage concerns. Portfolio implication: Selective opportunities in outperforming revenue growers like Eli Lilly/Penske, monitor SPAC closes for volatility.

25 high priority 21 medium 46 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Industrials focus, including media, pharma, banks, retail, and select industrials like GPC and GNK), key themes include mixed financial performance with revenue growth in 6/15 detailed reporters (avg +6% YoY, e.g., Dollar General +5.2%, QIAGEN +6%) offset by widening losses in 8/15 (avg +40% YoY, e.g., Urban One net loss +39%, Milestone Pharma +52%). M&A activity surges with accretive deals like Prestige's $1.045B Breathe Right acquisition (11x EBITDA, immediately accretive to EPS/FCF) and bank mergers (Stock Yards, Independent Bank), signaling consolidation. Capital allocation leans toward equity raises/financings (Benitec +92% cash, Palisade +$134M) amid cash burn concerns. Insider/leadership signals neutral with resignations (GPC CIO, FIS CPO) but positive appointments (Global Indemnity COO). Forward catalysts cluster in H1 2026: deal closes (Prestige H1 FY27), earnings (Civista Apr 22), AGMs (multiple Apr-May). Portfolio implication: Favor acquisitive consumer/health names over loss-making media/pharma; monitor bank NIM compression (Chain Bridge -7 bps).

29 high priority 21 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 20, 2026

Filings from the S&P 500 Energy stream reveal a mix of capital raising initiatives and modest operational updates in energy-adjacent sectors like oil tankers, with Okeanis Eco Tankers reporting a slight 0.4% YoY revenue decline to $391.5M for 2025 despite 1.3% TCE growth to $265.4M driven by 1.4% higher operating days at 5,025. Papa Medical's S-1/A signals IPO readiness with $15M gross proceeds targeted at $4/share, underscoring funding for hemp-derived products potentially tied to energy-alternative markets. Bioxytran completed a $1.2M private placement at $0.055/share, issuing 21M shares and warrants, reflecting positive sentiment amid working capital needs. AParadise Acquisition Corp.'s 425 filing promotes a SPAC merger with Enhanced Games, highlighting a May 24, 2026 catalyst event amid regulatory shift hopes for peptides. Portfolio-level trends show 1/4 filings with YoY revenue contraction (Okeanis -0.4%), but positive capital inflows averaging ~$10M+ per issuance; mixed sentiments dominate (50% mixed), with new issuances bullish. Key implication: Energy services face flat TCE rates (-0.1% YoY at $52,823), pressuring margins, while SPACs and placements offer entry points ahead of catalysts.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Financials stream focus, data spans tech, health, retail, SPACs), mixed sentiment prevails in 70% of material filings (>5/10), with 12/20 10-Ks showing revenue growth averaging 72% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%) but net losses widening in 8/12 by avg 55% YoY due to op ex surges and impairments. Margin expansions noted in 5 cos (QIAGEN +1339bps gross, Latham +320bps, Dollar General +107bps), contrasting compression elsewhere; M&A/SPAC activity peaks with Embecta/Pelican deals closing soon, Prestige accretive acq. Capital allocation lean: News Corp $1B buyback ongoing, limited dividends/insider trades (no major buys/sells flagged). Proxy season ramps with 15+ AGMs Apr-May 2026 as catalysts; Financials-specific: Civista Q1 earnings Apr22, Metro Bank AI push/headcount +10%. Portfolio implication: Favor rev accelerators with margin inflection (Dollar General, Latham) over loss-makers; watch SPAC redemptions (Pelican 63%) for dilution risks.

34 high priority 16 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 20, 2026

Across 50 8-K filings from March 20, 2026, the dominant theme is widespread executive churn with 17 instances of resignations, appointments, or transitions (e.g., AIR Industries CEO change, Nu Skin interim CFO), mostly neutral sentiment but signaling potential leadership instability in small/mid-caps. M&A and transaction activity is robust in healthcare/consumer sectors, highlighted by Prestige Consumer's $1.045B accretive Breathe Right acquisition (11x EBITDA multiple, H1 FY27 close) and Embecta's £150M Owen Mumford deal (mixed, accretive post-FY28), alongside KORE's $9.25/share cash merger. Period-over-period trends are sparse but mixed: Merlin Labs +515% YoY revenue to $7.6M (2025 vs 2024) yet net losses +35% to $74.8M; Spruce Biosciences net loss -26% YoY to $39M (FY25 vs FY24) with cash to early 2027; Beasley Broadcast -8.7% revenue CAGR to $206.2M FY25E (vs FY23); Prestige historical +3.4% revenue CAGR FY20-25. Distress signals emerge in Zynex bankruptcy (equity cancellation, delisted to ZYXIQ) and Trinseo covenant waivers post-nonpayment (expire Apr 2026). Positive financing trends include Fortive's $2B rev facility, TG Therapeutics' $750M term loan (SOFR+4.75%), and multiple amendments enhancing liquidity. Overall, actionable alpha in accretive M&A catalysts and takeouts outweigh risks from churn and isolated distress, with healthcare outperforming on growth vs media/energy declines.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 20, 2026

Across the 8 S&P 500 Technology stream filings, dominant themes include robust revenue growth in core software players like Snowflake (29% YoY to $4.68B) contrasted with persistent operating losses and slight net retention declines, signaling scaling challenges amid high R&D and sales spend; governance and compensation disclosures in proxies like Cogent reveal mixed incentive achievements (152% AWR CAGR target hit but 79% GP) and large LTIP grants up to 551k RSUs for CEO, indicating long-term alignment. SPAC and name-change activities (dMY to Horizon Quantum, Muzero unit separation, AParadise merger promo) highlight quantum and tech-enabled merger momentum, though with unproven models and regulatory risks. Neutral proxy solicitations in non-core names like Genco and funds show routine governance without financial trends, while limited period-over-period data points to portfolio-level revenue acceleration (e.g., Snowflake's 42% RPO growth outlier) but stable-to-compressing margins (Snowflake gross 67% flat YoY, opex % improving modestly). Overall, mixed sentiment prevails with bullish growth signals outweighed by profitability concerns, creating opportunities in high-growth tech names ahead of catalysts like LTIP vesting and meetings. Critical implications: Investors should prioritize Snowflake's RPO momentum and Cogent's insider-aligned comp over SPAC risks, watching for Q1 2026 earnings to validate trends.

5 high priority 3 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 20, 2026

Across 12 NASDAQ-100 related filings from March 20, 2026, proxy season dominates with 5 DEF/DEFA14A filings signaling imminent annual meetings and governance focus, while financial disclosures reveal mixed period-over-period trends: Zegna's FY2025 revenue declined 1.5% YoY to €1,917M but profit surged 20.5% YoY to €109M on 90 bps gross margin expansion; IPM reported FY2025 revenue of $23.6M with net loss down 42% YoY and Q4 Adjusted EBITDA turning positive post-transformation. Positive highlights include Gilead's robust HIV/oncology pipeline with up to 7 launches by 2033 and bulevirtide potential in 2026, AITX's new AI security order, and IPM's accretive acquisition adding 17k customers. Critical risks emerge in Faraday Future's Nasdaq delisting notice for sub-$1 bid price, granting 180 days to September 16, 2026, compliance. Portfolio-level patterns show profitability resilience amid revenue softness in luxury/shipping, SPAC liquidity/m erger progress, and limited insider details but LTIP grants signaling long-term alignment in Cogent/Gilead. Actionable implications favor monitoring pharma catalysts and avoiding delisting risks, with capital allocation tilting toward acquisitions/RSUs over dividends.

6 high priority 6 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 20, 2026

Across the 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip adjacent with diverse small/mid-caps), financial performance is mixed: 14/25 annual reports (10-K/20-F) show revenue growth averaging +35% YoY (outliers like Aeva +99%, Yellowstone +52%), but 11 report declines averaging -15% YoY (e.g., Urban One -16.7%, Scorpio Tankers vessel rev -25%), with net losses narrowing in 8 cases (avg -15%) amid margin expansions in 6 (e.g., QIAGEN +1330 bps to 62.2%). M&A activity surges with 4 deals (KORE $9.25/share cash merger, Kennedy-Wilson merger, Stock Yards/Field & Main 0.655x exchange), while capital allocation features dividends (Energy Services $0.03/share), reverse splits (FuboTV 1:12), forward splits (Climb 4:1), and financing (Aptiv tender upsized to $1.371B). Corporate events dominate with 15+ AGMs/proxies in April-May 2026, signaling governance focus; insider conviction low (no buys, some holdings detailed in proxies). Sector patterns include advertising/media weakness, AI/tech momentum, shipping volatility, and bancorp stability. Actionable implications: Favor growth outliers like Aeva/AITX for alpha, monitor merger proxies/merger risks, avoid revenue decliners amid portfolio-level margin compression in cyclicals (-200 bps avg in 5 shipping/media firms).

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 20, 2026

Across 50 SEC filings for March 20, 2026, dominant themes include advancing SPAC mergers (CoinShares, Einride, Pelican/Greenland) with high redemptions signaling investor caution, accretive M&A in healthcare (Embecta, Prestige, PSA/NSA), and robust revenue growth in tech/aerospace (Aeva +99% YoY, Firefly +163% YoY) offset by widening losses and yield compression in BDCs/investment firms (avg yield drop to 9.1% from 10.0%). Retail (Dollar General +5.2% YoY sales, +107 bps gross margin) and biotech (Cellectis +61.7% revenue) show resilience, but REITs like Belpointe report surging losses (+68% YoY) amid debt growth (+47%). Aggregate trends: 12/20 financial reporters grew revenue >50% YoY (avg +80%), but 8/12 saw net losses widen (avg +40%), with mixed sentiments in 70% of high-materiality filings. M&A valuations appear reasonable (Prestige 11x EBITDA, Embecta £150M for £69M rev), while SPAC redemptions averaged 60%+. Implications: Opportunities in post-merger listings and accretive deals, risks in dilutive financings and operational cash burns.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 20, 2026

Across the 50 filings in the S&P 500 Consumer Discretionary stream (with broader exposure via SPACs, M&A targets, and adjacents), overarching themes include robust revenue growth in high-flyers like Firefly Aerospace (+163% YoY), FiEE (+868% YoY), and Snowflake (+29% YoY), contrasted by margin pressures and widening losses in scaling firms (e.g., AutoZone op profit -1.2% YoY, Scorpio Tankers net income -49% YoY). Retail standouts like Dollar General showed resilient +5.2% sales growth and +107 bps gross margin expansion, while capital allocation leaned toward buybacks ($250M at First Industrial, AutoZone $742M) and dividends (Energy Services $0.03/share). M&A activity surged with UniFirst-Cintas deal (H2 2026 close) and NSA-Public Storage, signaling consolidation; insider moves were muted but resignations prevalent (e.g., FIS CTO, Lifeward director). Portfolio-level trends: 12/20 revenue reporters posted >20% YoY growth (avg +150%), but 8/15 profitability metrics declined (avg net income -15%), with mixed sentiment (22 mixed, 10 positive). Forward catalysts cluster in Apr-May AGMs; watch Nasdaq compliance risks in Lifeward/FFIE. Implications: Tactical buys in growth retail/tech, caution on overlevered cyclicals amid mixed guidance.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 20, 2026

Across 29 filings in the USA S&P 500 Healthcare stream (with broader cross-sector context), dominant themes include the onset of 2026 proxy season with 15+ annual meetings clustered April-May, robust period-over-period profitability gains in select names (e.g., Eli Lilly $65.2B revenue, Spruce Biosciences net loss improved 26% YoY to $39M, Heritage Financial net income +56% YoY), and healthcare-specific catalysts like Gilead's pipeline advancements (7 HIV launches by 2033, bulevirtide 2026), Eli Lilly's superior Zepbound data (20.2% weight loss vs Wegovy 13.7%), Exact Sciences/Abbott merger closing March 23, and Artelo Biosciences' compelling Phase 2a trial (6.38% weight gain vs placebo loss). Margin trends mixed: expansions in Zegna (+90 bps gross to 67.5%) and Ameriprise (+40 bps adjusted to 26.9%) offset by compressions elsewhere (Zegna op margin -130 bps to 7.3%, Spruce G&A +16% YoY). Capital returns strong in financials (Ameriprise $3.4B +20% YoY, News Corp $1B repurchase), biotech financing mixed (Cingulate dilution risk from $25M facility, Spruce $50M loan). Healthcare outliers show pipeline conviction (Gilead, Lilly, Artelo positive sentiment 8-9/10 materiality) amid Nasdaq compliance risks (Lifeward negative 9/10). Portfolio implication: overweight pharma/biotech on catalysts, monitor governance votes and M&A closes for near-term volatility.

13 high priority 16 medium 29 total filings
· daily

Global High-Priority Regulatory Events — March 20, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include ongoing insolvency proceedings in Indian firms (e.g., AGS Transact, Quadrant Televentures), promoter share acquisitions signaling conviction (DCM Shriram), SPAC mergers with high redemptions (Pelican Acquisition), biotech trial successes (Artelo), and M&A/takeover activity (NSA, Embecta, CoinShares). Period-over-period trends show robust revenue growth in 12/50 filings averaging +90% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%), but persistent net losses widening in 8 cases (avg +50% YoY) amid margin volatility and high R&D/debt costs; gross margins expanded notably in QIAGEN (+1,330 bps to 62.2%). Insider/promoter activity is bullish in 4 Indian firms with +5-10% stake increases, while pledges/encumbrances flag leverage risks. Forward-looking catalysts cluster in Q1-Q2 2026: merger closings, CoC meetings, and trial escalations. Portfolio implications favor monitoring biotech/SPAC turnarounds and avoiding insolvency-exposed names, with alpha in revenue accelerators trading below peers.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 20, 2026

A surge of 5 new S-1 filings on March 20, 2026, highlights a robust IPO pipeline across crypto ETFs, biotech, consumer tech, quantum computing M&A, nuclear energy, and early-stage tech, with the 6th providing context on governance evolution. Positive sentiments dominate in biotech (Artelo) and quantum (IonQ merger), driven by superior trial outcomes (e.g., Artelo's 6.38% weight gain vs -5.42% placebo) and strategic vertical integration, while mixed/neutral tones prevail elsewhere amid volatility risks and competition. No broad revenue/margin period-over-period declines reported, but GoPro notes recent market share losses contrasting Artelo's strong Phase 2a efficacy metrics. Key developments include Artelo's dose escalation to 1,300 micrograms and IonQ's $15/share + stock merger with SkyWater, signaling sector consolidation. Portfolio-level patterns show high equity comp in pre-IPO firms (X-energy CEO $10.5M, 88% stock awards), indicating management alignment, with implications for near-term listings on Nasdaq/NYSE boosting liquidity and alpha in high-volatility names.

6 high priority 6 total filings
· daily

US Earnings Financial Results SEC Filings — March 20, 2026

Across 50 10-K and 10-Q filings from March 20, 2026, primarily FY2025 results, a dominant mixed sentiment prevails with 70% of named companies showing revenue growth averaging 40% YoY in high-growth sectors like aerospace (Firefly +163%), tech (Snowflake +29%, Aeva +99%), and retail (Dollar General +5.2%, Victoria's Secret +5%) but persistent net losses widening in 60% of cases due to high opEx/R&D and impairments. SPACs (e.g., Pelican, Bluerock, Jackson) represent ~20% of filings, holding intact trust accounts with interest income driving modest profits amid pre-merger deficits. BDC/investment vehicles (11 filings) expanded assets/portfolios 50-80% YoY with investment income up 50-110%, though yields compressed 100bps to 9.1% on average, signaling rate sensitivity. ABS servicing compliance in 15+ unknown filings remains routine/neutral with no deficiencies, focusing on standard timeframes (2-90 days). Capital allocation leans toward financing inflows ($100M+ in Aeva, Firefly) over dividends/buybacks, with outliers like AutoZone's $742M buybacks. Portfolio-level trends highlight growth resilience but profitability challenges, implying near-term catalysts from guidance-embedded EBITDA targets (Wellgistics to 2026) and product launches (Milestone PSVT in 2026).

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 20, 2026

Across 50 DEF 14A proxy statements, a dominant theme is robust 2025 performance with 18 companies reporting YoY revenue growth averaging 10%+ (e.g., Ameriprise +6% rev/$18.2B, Goldman +9%/$58.3B, Inspire +14%/$912M, Eli Lilly $65.2B), strong EPS expansions (Goldman +27% to $51.32, Ameriprise +12% to $39.34), and margin improvements (Latham +320bps gross margins, Pentair +170bps adj ROS), though 6 showed declines like Avalon net income -76% YoY. Positive sentiment prevails in 22 filings (44%), mixed/neutral in 28, with no explicit insider selling but high ownership concentrations signaling alignment (e.g., Preformed Line 33% insiders). Capital allocation favors shareholders via dividend hikes (Ameriprise 21st consecutive +20% returns, Penske $182M buybacks/1.8% shares), buybacks, and LTIPs tied to CAGR targets. Portfolio-level trends highlight financials/healthcare outperformance vs industrials mixed results, with pay-for-performance evident (Cogent CEO 152% AWR target payout). AGMs cluster April 29-May 13, 2026 as key catalysts for comp votes, auditor ratifications, and equity plan amendments. Market implications: Buy dips in high-performers pre-vote, monitor pay scrutiny in decliners.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 20, 2026

Across 38 SEC filings on US executive and director changes dated March 20, 2026, the dominant theme is high C-suite and board turnover with 70% neutral sentiment, including 18 resignations/retirements (mostly voluntary, no disagreements cited except one), 12 appointments/promotions of experienced executives, and 5 salary/bonus adjustments signaling retention efforts. No widespread period-over-period financial deterioration evident, but isolated YoY EPS gains (e.g., Nu Skin) and equity grants contrast with severances totaling $810k+ across cases like Aeries ($265k), CleanCore ($500k), reAlpha ($46k). Biotech/pharma (Aquestive, AN2, Iovance) shows positive hires amid FDA catalysts, while tech (SMCI, Rigetti, Roblox) mixes promotions with legal risks and board exits. Portfolio-level pattern: 15 CFO/CIO changes suggest transition risks in growth sectors; insider conviction mixed with promotions (e.g., Kite Realty CFO) but concerns from disputes (APHP). Implications: Bullish for experienced hires in REITs/fintech, bearish for legal overhangs; watch Q2 2026 AGMs and successor searches for volatility.

38 high priority 38 total filings